A gene known to be mutated in many different cancers, but thought to be relatively unimportant in melanoma, may be a key indicator of how the disease will respond to radiation therapy and whether it will spread.
Votes, not baskets, will propel Cornucopia House to the Final Four in a national competition for a $25K mobile technology grant from AtlanticBT.
Chapel Hill, NC – Debbie C. Dibbert, Director of External Affairs at UNC Lineberger Comprehensive Cancer Center, has been elected president of the National Association of Cancer Center Development Officers (NACCDO). She will serve a two-year term.
CHAPEL HILL, N.C. – A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.
Chapel Hill, NC – Why do some cancers spread rapidly to other organs and others don’t metastasize? A team of UNC researchers led by Norman Sharpless, MD, have identified a key genetic switch that determines whether melanoma, a lethal skin cancer, spreads by metastasis.
WCHL named Jennifer Bowman a Hometown Hero for June 11, 2012. Each weekday the station selects a Hometown Hero who goes “over and above the call of duty,” exemplifying excellent service and dedication to others in the community.
Deborah Mayer, PhD, RN, AOCN, FAAN, associate professor in the UNC School of Nursing, has been appointed to a three-year term on the Cancer Survivorship Committee of the American Society of Clinical Oncology.
James P. Evans, MD, PhD, Bryson Distinguished Professor of Genetics and Medicine, is quoted in an article discussing the fetal genome and the possibility of clinic procedures being introduced in the next couple of years.
Kurt Ribisl, PhD, is co-author of the article “Internet Alcohol Sales to Minors” published online ahead of print in the May 2012 issue of the Archives of Pediatrics & Adolescent Medicine.
Victoria Bae-Jump, MD, PhD, has received a two-year $200,000 grant from the Department of Defense, to study “Preclinical and Clinical Investigations of the Impact of Obesity on Ovarian Cancer Pathogenesis.”
Congratulations to the N.C. Children’s Hospital for receiving top rankings in 10 out of 10 clinical categories in U.S. News & World Report’s 2012-13 “America’s Best Children’s Hospitals” list. The N.C. Children’s Hospital is ranked 26th in cancer.
More than 150 faculty, students, and fellows gathered in the Alumni Center to hear talks on HPV and Cancer given by UNC Lineberger scientists from basic, translational science, clinical, population science, and global perspectives.
UNC surgeon-scientist Dr. Nancy DeMore says, “As a physician, I’m acutely aware of how much more we need to learn about breast cancer and how urgently we need better therapies. It really gives me hope to be in the lab and to know that I’m working towards something that may make things better for patients.”
Chapel Hill - Patricia Cadle, MRE, BCC, Oncology Chaplain at UNC Health Care’s Department of Pastoral Care, was honored as the 2012 Chaplain of the Year by the North Carolina Chaplains’ Association. This award is presented annually at the Association’s spring conference in recognition of “distinguished ministry in pastoral care” to a chaplain “who serves patients, community and colleagues with grace and innovation.”
CHAPEL HILL, N.C. – Blue Cross and Blue Shield of North Carolina (BCBSNC) has announced Dr. Lisa Carey, Medical Director of the University of North Carolina at Chapel Hill (UNC) Breast Center and Associate Director of UNC Lineberger Comprehensive Cancer Center, as the newest member of its board of trustees.
Chapel Hill, NC – Multiple research projects – including a 2006 study conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.
Chapel Hill, NC – Does hepatitis C cause liver cancer due to inflammation associated with the disease, or does the virus interact with host cells in a different way to promote the development of cancer?
Victoria Bae-Jump, MD, PhD will serve a two-year term as a junior investigator on the Gynecologic Cancer Steering Committee of the National Cancer Institute, a member institute of the National Institutes of Health.
In the processes of treating most cancers, one of the key pieces of information is the appearance of the tumor under the microscope using a technique called light microscopy. In lung cancer, for example, the appearance of the tumor determines both which chemotherapies are safe and which chemotherapies are effective. In addition, tumor appearance also suggests which patients should be tested for mutations that can be targeted by some of the most effective and safest drugs on the market.
Chapel Hill, NC – Norman E. “Ned” Sharpless, MD, professor of medicine and genetics and Associate Director for Translational Research at UNC Lineberger Comprehensive Cancer Center has been appointed the Wellcome Distinguished Professor in Cancer Research. The professorship was established by the School of Medicine in 1988 with gifts from the Burroughs Wellcome Fund and the William A. Smith Trust of Wadesboro, NC. The gifts were supplemented by the state of North Carolina the Distinguished Professors Endowment Trust Fund to create the endowed professorship.
The finding presents a possible explanation for why so many cancers possess not just genomic instability, but also more or less than the usual 46 DNA-containing chromosomes.
Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.